Core Insights - Illumina, Inc. (ILMN) and Labcorp (LH) have expanded their collaboration to enhance precision oncology through next-generation sequencing (NGS) solutions, which is expected to solidify Illumina's position in the oncology market [1][3] Company Developments - Following the collaboration announcement, ILMN's shares increased by 1.8%, closing at $122.95, indicating positive market sentiment [2][10] - Illumina's TruSight Oncology assay, TSO 500, is experiencing increased utilization and broader adoption, contributing to the company's growth in cancer genomics [2] - The collaboration aims to co-commercialize Labcorp's FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx alongside Illumina's FDA-approved TruSight Oncology Comprehensive for solid tumor profiling, expanding access to both tissue and liquid biopsy testing [5] Research and Clinical Utility - The collaboration will focus on developing new tests for advanced oncology research, including comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS) [6] - A study published in Frontiers of Oncology demonstrated that CGP identified variants associated with targeted therapies in over 72% of non-small cell lung cancer (NSCLC) patients, showcasing the clinical utility of CGP [7][8] Market Outlook - The global oncology market is projected to reach $866.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.8% from 2024 to 2034, driven by rising cancer incidence and technological advancements [9] - Illumina currently has a market capitalization of $18.48 billion and an earnings yield of 4.25%, significantly outperforming the industry's -15.13% [4]

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing Accessibility StatementSkip Navigation SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include pr ...

Illumina Stock Sees RS Rating Jump To 82 | Investor's Business Daily BREAKING: Futures Rise, Oil Prices Fall; Micron Earnings, Fed Meeting Due One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Illumina (ILMN) stock cleared that benchmark Monday, with a jump from 77 to 82 Monday. Hone Your Stock-Picking Skills By Focusing On These Factors This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of othe ...

Core Insights - Illumina has announced a strategic collaboration with Veritas Genetics to form a consortium aimed at integrating population-scale whole-genome sequencing into everyday healthcare, enhancing early risk detection and data-driven prevention [1][2][3] Group 1: Collaboration Objectives - The collaboration focuses on data-driven precision medicine, enabling individuals to utilize whole-genome data for earlier disease risk identification and personalized prevention strategies [2][5] - The consortium aims to shift healthcare from reactive treatment to proactive prevention, particularly in areas such as hereditary cancer and cardiometabolic diseases [5][6] Group 2: Technological Integration - Veritas will develop and validate workflows based on Illumina's sequencing and informatics technologies, including whole-genome sequencing and AI-enabled insights [4][6] - The collaboration will provide a streamlined member experience with simple sample collection, clear education, and access to genetic counseling [6] Group 3: Expected Outcomes - The initiative is designed to create integrated care pathways for actionable findings, including confirmatory testing and guideline-aligned screening [6] - The consortium aims to deliver an opt-in preventive genomics program that connects genomic insights to appropriate interventions [6]

Core Insights - Illumina's shares have increased by 44.8% over the past year, significantly outperforming the industry and S&P 500 [1][9] - The company is focused on long-term growth through its core sequencing business, multiomics expansion, and enhanced services, data, and software capabilities [2][4] Company Performance - Illumina's core sequencing business is experiencing growth, particularly with the NovaSeq X platform, which has driven a 7% increase in ex-China revenues in Q4 [4][9] - The company achieved its second-highest quarterly placements of NovaSeq X since its launch in 2023 [5] Strategic Initiatives - Illumina is expanding into multiomics through acquisitions, such as SomaLogic, and has launched the Illumina Connected Multiomics platform [6] - The introduction of the BioInsight business and the Billion Cell Atlas data product has garnered strong interest from biopharma partners [7] Financial Health - Non-GAAP gross margins improved by 165 basis points, and non-GAAP operating margins expanded by 400 basis points year-over-year [10] - As of the end of Q4, Illumina had cash and short-term investments totaling $1.63 billion, with $500 million in short-term debt, indicating a strong liquidity position [10] Market Challenges - In March 2025, China imposed a ban on imports of Illumina's NGS sequencers, which poses a significant challenge in a market with high sequencing demand [11] - The company is also facing macroeconomic pressures, including inflation and currency fluctuations [11] Future Projections - The Zacks Consensus Estimate predicts a 6.2% increase in EPS for 2026 and a 14.8% increase for 2027, with revenues expected to grow to $4.54 billion in 2026 and $4.83 billion in 2027 [12]

Core Insights - The Alliance for Genomic Discovery (AGD) has expanded its dataset to over 312,000 whole genomes with longitudinal clinical data, with Regeneron Genetics Center (RGC) joining as the tenth member [1] - A new initiative will add 50,000 whole genomes paired with proteomic data, with GSK being one of the first participants in this multiomic expansion [1] - The integration of high-quality clinical and genomic data with advanced AI is expected to enhance drug discovery and patient outcomes [1] Dataset Expansion - The AGD dataset is now one of the largest collections of whole genome sequences, enriched with clinical data from a leading academic medical center [1] - The addition of RGC will significantly scale the database, which already includes nearly 3 million sequenced exomes and de-identified electronic health records (EHRs) [1] - The dataset aims to facilitate precise disease cohort definitions and has already contributed to discoveries in autoimmune diseases and obesity [1] Proteomics Initiative - The new dataset will consist of 50,000 paired whole-genome and proteomic samples, enhancing the molecular depth of the AGD dataset [1] - This initiative is designed to accelerate target discovery and therapy development by providing deeper biological insights [1] - The diverse genetic ancestry within AGD allows for the study of population-specific genetic variants and their associated proteins [1] Collaboration and Goals - RGC aims to uncover large-effect protective genetic factors to identify high-confidence drug targets [1] - The collaboration reflects ongoing partnerships with Illumina and the biopharma community to build large-scale population genomics consortia [1] - The integration of proteomics with comprehensive datasets is expected to pinpoint drug targets linked to human diseases [1]

Core Insights - Patient Opportunity Equity Strategy achieved a return of 5.99% net of fees in Q4 2025, outperforming the S&P 500 Index which returned 2.65% [1] - The overall market experienced a strong year with a return of 17.9%, marking the seventh-best three-year period in market history [1] - The strategy outperformed the S&P 500 for the third consecutive year with a total return of 26.1% in 2025 [1] Company Focus: Illumina, Inc. (NASDAQ:ILMN) - Illumina, Inc. is a biotechnology company specializing in sequencing and array-based solutions for genetic and genomic analysis [2] - As of March 04, 2026, Illumina's stock closed at $128.97 per share, with a one-month return of -3.47% and a 52-week gain of 52.36% [2] - The company has a market capitalization of $19.72 billion [2] Performance and Outlook - Illumina was a top contributor in Q4 2025, driven by a stronger-than-expected third-quarter earnings report, with growth in clinical consumables exceeding expectations [3] - The core sequencing business is returning to a normalized growth and profitability profile, with improving confidence in demand durability and margin recovery [3] - Illumina reported revenue of $1.16 billion in Q4 2025, reflecting a 5% year-over-year increase on a reported basis and 4% on a constant currency basis [4] Hedge Fund Interest - Illumina is not among the 40 most popular stocks among hedge funds, with 46 hedge fund portfolios holding the stock at the end of Q4 2025, up from 45 in the previous quarter [4]

Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1][2]. Group 1: Zacks Style Scores - Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum methodologies, aiding investors in selecting stocks likely to outperform the market in the short term [3]. - Each stock receives a rating from A to F based on its characteristics, with A being the highest score indicating a better chance of outperforming [4]. - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7]. Group 2: Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that utilizes earnings estimate revisions to simplify portfolio building [8]. - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.86% since 1988, significantly outperforming the S&P 500 [9]. - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering the direction of earnings estimate revisions [10][11]. Group 3: Company Spotlight - Illumina Inc. - Illumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic and genomic analysis, serving various sectors including life sciences and oncology [12]. - The company holds a Zacks Rank of 3 (Hold) with a VGM Score of A, indicating potential for growth investors [13]. - Illumina is forecasted to achieve year-over-year earnings growth of 6.2% for the current fiscal year, with upward revisions in earnings estimates from analysts [13][14].

Core Message - The company successfully showcased its product roadmap at the AGBT conference, emphasizing its commitment to innovation and customer success [2] Group 1: Product Roadmap - The focus was on demonstrating the NovaSeq X, which has been a significant success, along with plans for additional flow cells to enhance customer offerings [2] Group 2: Competitive Landscape - The company highlighted its strategy to ensure continued innovation, positioning itself favorably against competitors like Roche [2]

Illumina FY Conference Summary Company Overview - **Company**: Illumina (NasdaqGS:ILMN) - **Event**: FY Conference at TD Cowen Global Healthcare Conference - **Date**: March 03, 2026 Key Industry Insights - **Product Roadmap**: Illumina showcased its innovation strategy at the AGBT conference, emphasizing the NovaSeq X platform and its capabilities for both high and low capacity applications [4][5] - **TruPath Technology**: Launched as a library prep solution that eliminates traditional library preparation time, allowing for genome sequencing at a cost of $395, which is positioned as the lowest price for high-quality genome sequencing [6][7] - **Spatial Technology**: Illumina is advancing spatial technology to analyze larger tissue samples, which has generated significant customer interest [8][9] - **Competitive Landscape**: Illumina acknowledges competition from Roche, highlighting differences in workflow and pricing models, and expresses confidence in its ability to compete effectively [11][12] Financial Guidance - **Growth Projections**: For 2026, Illumina projects organic growth of 1%-3% excluding China, with a potential upside if the clinical business performs better than expected [30][31] - **Operating Margin**: Targeting a 150 basis point improvement in operating margin, aiming for a 26% operating margin in the near future [31][32] - **Earnings Per Share (EPS)**: Anticipating double-digit growth in EPS, despite headwinds from the SomaLogic acquisition [32] Market Dynamics - **Clinical vs. Research**: The clinical segment is expected to drive growth, particularly in oncology, with a shift towards minimal residual disease (MRD) detection and early cancer detection [43][44] - **Research Challenges**: The research segment faces ongoing pressures, but Illumina remains optimistic about maintaining high single-digit growth in a competitive environment [52] Product Innovations - **Q70 Scores**: Illumina plans to introduce Q70 scores for high sensitivity MRD applications within the next 18 months, which is expected to enhance clinical applications [5][58] - **Protein Prep**: The acquisition of SomaLogic is expected to expand Illumina's capabilities in protein analysis, with a focus on reducing costs and increasing the number of proteins analyzed [64][68] - **BioInsight**: A new initiative aimed at creating large datasets for AI model training in biology, which will be monetized through subscriptions to pharmaceutical companies [92][96] Competitive Positioning - **Roche Comparison**: Illumina believes it is well-positioned against Roche, particularly with the TruPath technology, which offers unique insights and a simpler workflow compared to Roche's offerings [100][101] - **Market Sentiment**: Illumina's leadership expresses confidence in its competitive edge, citing strong R&D and commercial teams as key advantages [108] Conclusion - **Future Outlook**: Illumina is committed to strong growth in a competitive landscape, with a focus on innovation and customer success in both clinical and research applications [108]